Corvus Pharmaceuticals (CRVS) Equity Average (2022 - 2025)
Corvus Pharmaceuticals (CRVS) has 4 years of Equity Average data on record, last reported at $76.0 million in Q3 2025.
- For Q3 2025, Equity Average rose 138.86% year-over-year to $76.0 million; the TTM value through Sep 2025 reached $76.0 million, up 138.86%, while the annual FY2024 figure was $35.6 million, 24.84% down from the prior year.
- Equity Average reached $76.0 million in Q3 2025 per CRVS's latest filing, up from $64.8 million in the prior quarter.
- Across five years, Equity Average topped out at $85.1 million in Q2 2022 and bottomed at $22.5 million in Q4 2024.
- Average Equity Average over 4 years is $51.6 million, with a median of $48.0 million recorded in 2023.
- Peak YoY movement for Equity Average: plummeted 45.79% in 2024, then skyrocketed 138.86% in 2025.
- A 4-year view of Equity Average shows it stood at $60.4 million in 2022, then plummeted by 31.31% to $41.5 million in 2023, then tumbled by 45.79% to $22.5 million in 2024, then soared by 237.94% to $76.0 million in 2025.
- Per Business Quant database, its latest 3 readings for Equity Average were $76.0 million in Q3 2025, $64.8 million in Q2 2025, and $40.9 million in Q1 2025.